United States Patent 6,534,070: Scope, Claims, Expiration, Orange Book Status, and Azelaic Acid Patent Landscape

US Patent 6,534,070 protects a specific azelaic-acid hydrogel formulation containing polyacrylic acid, a triacylglyceride, propylene glycol, a polysorbate, lecithin, water, and salts. The patent also covers topical administration and treatment of rosacea and several other dermatological conditions. Its enforceable US patent term has expired, eliminating current infringement risk from this patent alone. The claim structure remains relevant for historical generic litigation, formulation benchmarking, and freedom-to-operate analysis.

What does US Patent 6,534,070 protect?

US 6,534,070 protects a multi-component topical hydrogel rather than azelaic acid as a molecule or as a broad therapeutic concept.

The independent composition claim requires all of the following:

Required element	Claim 1 requirement
Azelaic acid	5% to 20% by weight
Polyacrylic acid	At least one
Triacylglyceride	0.5% to 5% by weight
Propylene glycol	Present
Polysorbate	At least one
Lecithin	Present
Aqueous phase	Water and salts
Dosage form	Hydrogel

The use of “comprises” makes the composition claim open-ended. A product can contain additional excipients and still fall within the claim if it includes every required element. The claim does not require a particular brand, manufacturing process, particle size, pH, viscosity, package, or dosing schedule.

The patent is associated with the azelaic acid 15% gel formulation marketed as Finacea. Finacea Gel 15% contains azelaic acid, carbomer, medium-chain triglycerides, propylene glycol, polysorbate 80, lecithin, benzoic acid, disodium edetate, and purified water. Those ingredients correspond closely to the claimed formulation architecture and to dependent claim 12, which expressly adds benzoic acid. [1]

How do the ten issued claims divide the patent scope?

Claims 1 through 7 cover compositions. Claims 8 and 9 cover therapeutic use. Claims 10 through 12 narrow the composition by concentration or ingredient.

Composition claims

Claim 1 is the core formulation claim. It requires a hydrogel with azelaic acid at 5% to 20% and the specified excipient classes.

Claim 2 limits the composition to topical administration. Because claim 1 already describes a hydrogel consistent with topical use, claim 2 provides a narrower but commercially important claim directed to dermatological delivery.

Claim 3 limits lecithin to soybean lecithin.

Claim 4 requires lecithin in an amount greater than 0% and up to 1% by weight.

Claim 5 imposes concentration ranges for four excipient classes:

Polyacrylic acid: 0.5% to 2%
Triacylglyceride: 0.5% to 5%
Propylene glycol: 5% to 15%
Polysorbate: 0.5% to 3%

Claim 6 is the most formulation-specific claim. It targets approximately:

Polyacrylic acid: 0.75% to 1.25%
Triacylglyceride: 1% to 3%
Propylene glycol: 8% to 12%
Polysorbate: 1.5% to 2.5%

The patent text states “10±2-%” for propylene glycol. Read in context, that notation represents 10% plus or minus 2%, or 8% to 12%.

Claim 7 permits additional physiologically compatible pharmaceutical vehicles or adjuvants. Because claim 1 is already open-ended, claim 7 has limited independent exclusionary value. Its practical function is to confirm that conventional pharmaceutical excipients do not remove a product from the claim.

Method-of-use claims

Claim 8 covers treatment of:

Rosacea
Presbyderma
Melasma
Acne
Skin irritations

The method requires administering a therapeutically effective amount of the claim 1 composition. Claim 9 limits administration to topical use.

These are composition-dependent method claims. A method using azelaic acid in a different formulation would not literally satisfy claim 8 because the administered composition must meet claim 1.

Narrowing claims

Claim 10 narrows azelaic acid to 10% to 18% by weight. A 15% azelaic acid gel falls within this range.

Claim 11 permits lecithin at greater than 0% to 3% by weight. It is broader than claim 4 with respect to the upper lecithin concentration, but remains dependent on claim 1.

Claim 12 adds benzoic acid. This claim is particularly relevant to products that use benzoic acid as a preservative or formulation stabilizer.

What formulation would most closely match the patented product?

A formulation with approximately 15% azelaic acid, 1% carbomer or another polyacrylic acid, 2% medium-chain triglycerides, 10% propylene glycol, 2% polysorbate 80, a low concentration of lecithin, water, salts, and benzoic acid would closely track claims 1, 5, 6, 10, and 12.

A representative claim-mapping analysis is:

Formulation characteristic	Likely claim relevance
15% azelaic acid	Claims 1 and 10
Carbomer at approximately 1%	Claims 1, 5, and 6
Medium-chain triglycerides at approximately 2%	Claims 1, 5, and 6
Propylene glycol at approximately 10%	Claims 1, 5, and 6
Polysorbate 80 at approximately 2%	Claims 1, 5, and 6
Soybean lecithin	Claim 3
Lecithin below 1%	Claim 4
Benzoic acid	Claim 12
Hydrogel	Claim 1
Topical rosacea treatment	Claims 2, 8, and 9

The strongest historical infringement theory would have involved a 15% azelaic acid topical gel with the same or substantially similar excipient system. The presence of azelaic acid alone would not have been enough.

When did US Patent 6,534,070 expire?

The patent issued on March 18, 2003. Its ordinary US patent term ran from the applicable nonprovisional or international filing date and is reported as expiring on June 22, 2020. The USPTO record identifies the patent as expired. [2]

Event	Date
US patent grant	March 18, 2003
Reported US patent expiration	June 22, 2020
Current status	Expired
Current patent-based US blocking right	None from this patent

The expiration date is separate from FDA regulatory exclusivity. Patent expiration does not itself determine whether an ANDA may be approved, but it removes the patent as a continuing statutory barrier once any applicable regulatory exclusivity has also ended.

What is the Orange Book status of US 6,534,070?

US 6,534,070 was listed in connection with Finacea Gel 15%, the azelaic acid product approved under NDA 021470. The listed patent covered the formulation and use of the product rather than the chemical identity of azelaic acid. [1, 3]

The patent is no longer an effective Orange Book barrier because its term has expired. An expired patent may remain visible in historical FDA records, but it cannot support a current injunction against an ANDA applicant.

FDA regulatory status of Finacea

Finacea Gel 15% is an FDA-approved topical prescription product for the inflammatory papules and pustules of mild-to-moderate rosacea. The reference product contains 15% azelaic acid in a gel vehicle. [1]

The relevant regulatory distinction is:

FDA approval status: Finacea remains an approved reference product unless withdrawn.
Patent status: US 6,534,070 is expired.
Regulatory exclusivity: Any original exclusivity period has ended.
Generic pathway: Azelaic acid 15% gel products may use the ANDA pathway if they satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and manufacturing.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification would have been relevant while US 6,534,070 was listed and unexpired. A generic applicant could have certified that the patent was invalid, unenforceable, or would not be infringed. Once the patent expired in 2020, the commercial significance of a Paragraph IV challenge ended.

The FDA Orange Book and product approval records do not establish a current Paragraph IV dispute involving this patent. Any historical ANDA litigation would need to be evaluated separately from the patent’s present enforceability. [3]

The practical launch sequence was:

An ANDA applicant could address the listed patent through Paragraph IV, a section viii statement where appropriate, or a certification reflecting expiration.
A successful Paragraph IV filing could trigger a 30-month stay if the patent holder filed timely litigation.
After patent expiration, the patent no longer supported a continuing 30-month stay or an injunction based on future commercial launch.
Generic launch risk shifted from patent validity to FDA approval timing, manufacturing readiness, supply, and market access.

Which claims would be most vulnerable to a design-around?

The patent has multiple formulation-specific limitations. A competing developer could historically have reduced literal infringement risk by removing or changing one required element.

Design-around approach	Effect on claim exposure
Omit lecithin	Avoids literal infringement of claim 1
Use a non-hydrogel cream, foam, suspension, or lotion	Avoids the hydrogel limitation
Replace the triacylglyceride system	May avoid claim 1 if no qualifying triacylglyceride remains
Use a different solubilizer instead of polysorbate	May avoid claim 1
Replace propylene glycol	May avoid claim 1
Use a non-polyacrylic thickener	May avoid claim 1
Use azelaic acid below 5% or above 20%	Avoids claim 1, subject to other claim construction issues
Use a nonaqueous vehicle	Avoids the aqueous-phase limitation
Use a different active ingredient	Avoids the azelaic-acid limitation

The most direct design-around would have been a topical azelaic acid formulation that omitted lecithin or substituted a different gelling and emulsification system. A formulation could also avoid the narrower claims while still implicating claim 1. For example, a product with 15% azelaic acid and the same general vehicle but without lecithin would fall outside the literal wording of claim 1.

Because the patent is expired, these design-around options now matter primarily for historical analysis, patent landscaping, and comparison with later patents.

How strong was the patent estate?

The US estate was commercially focused but technically narrow.

Strengths

The claims covered the combination of azelaic acid with a defined hydrogel excipient platform.
The 15% strength used in Finacea fell comfortably within the claims.
Dependent claims addressed commercially plausible concentrations.
Claim 12 captured benzoic acid-containing versions.
The method claims covered rosacea and other dermatological conditions.

Limitations

The patent did not claim azelaic acid broadly.
It did not claim all topical azelaic acid products.
It required lecithin, which created a clear formulation design-around.
It required a hydrogel and aqueous phase.
The claim language did not cover every cream, foam, lotion, emulsion, or suspension.
The patent term has ended.

The estate was therefore strong against close copies of the Finacea-type gel during its term, but weaker against materially different vehicles and irrelevant as a current US exclusion right.

What other azelaic acid products compete with Finacea?

The principal US commercial comparison is between azelaic acid 15% gel and azelaic acid 20% cream products.

Product category	Strength	Dosage form	Typical regulatory route	Relationship to US 6,534,070
Finacea Gel	15%	Hydrogel	NDA	Closely aligned with the patented formulation
Generic azelaic acid gel	15%	Gel	ANDA	Patent term no longer blocks launch
Azelex and generic equivalents	20%	Cream	NDA/ANDA	May avoid the patent if the formulation lacks required elements
Compounded azelaic acid products	Variable	Cream, gel, foam	Compounding framework	Product-specific and generally outside Orange Book analysis

The 20% cream category is not automatically outside the patent because claim 1 reaches azelaic acid concentrations up to 20%. The decisive issue is whether the product also contains the claimed polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, lecithin, aqueous phase, salts, and hydrogel format.

Does biosimilar risk apply to azelaic acid?

No. Azelaic acid is a small-molecule active ingredient, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.

The principal regulatory and commercial risks are:

Formulation sameness or difference
Demonstration of bioequivalence
FDA product-specific requirements
Manufacturing scale-up
API sourcing
Pricing and pharmacy substitution
Reference-product market share

Biosimilar litigation and the Biologics Price Competition and Innovation Act do not apply to Finacea or to US 6,534,070.

What manufacturing and intellectual-property barriers remain?

US 6,534,070 no longer creates a manufacturing barrier. A current manufacturer must still manage technical risks associated with:

Uniform dispersion of azelaic acid
Hydrogel rheology
Carbomer neutralization and viscosity control
Compatibility of lecithin with the emulsion or dispersion system
Stability of polysorbate and triglyceride components
Preservative effectiveness where benzoic acid is used
Microbial control in an aqueous topical product
Scale-up mixing and deaeration
Container-closure compatibility
Control of particle size and product feel

Later patent families may protect specific manufacturing processes, delivery systems, packaging, polymorphs, or alternative formulations. Those rights cannot be inferred from US 6,534,070 and require a separate current patent search.

What geographic coverage did the patent provide?

US 6,534,070 provided rights only in the United States. Patent protection in Europe, Canada, Japan, or other jurisdictions depended on separate national or regional family members.

The US patent did not create worldwide exclusivity. A company assessing international launch rights must review:

National family members
Local expiration dates
Patent-term adjustments or supplementary protection certificates
Local Orange Book or equivalent listings
Regulatory exclusivity
National formulation and use claims
Local litigation and settlement records

The expiration of the US patent does not establish expiration of corresponding foreign patents.

What revenue exposure was associated with this patent?

The patent was linked to the Finacea 15% gel franchise, but the patent itself did not control all azelaic acid revenue. Commercial exposure depended on the reference product’s market size, generic substitution, payer coverage, channel mix, and competition from 20% creams and nonprescription or compounded products.

After June 2020, the principal revenue risks were generic entry and price erosion. The patent no longer supported premium pricing or delayed competition. Public product-level revenue figures should be attributed to the marketing authorization holder and product franchise, not treated as revenue generated by the patent.

What litigation and settlement issues are relevant?

The key historical litigation question would have been whether an ANDA product reproduced the claimed formulation and whether the listed claims were valid and enforceable. The relevant defenses would have included:

Noninfringement based on omission of lecithin
Noninfringement based on a non-hydrogel dosage form
Noninfringement based on a different thickener or surfactant
Obviousness based on prior topical azelaic acid formulations
Lack of written description or enablement for broad excipient classes
Indefiniteness involving concentration ranges or “at least one” components
Patent-term and regulatory-status defenses

A settlement entered after a Paragraph IV filing could have governed the launch date of a generic before expiration. After the patent expired, any such settlement would have limited value unless it addressed separate patents, commercial terms, or regulatory restrictions.

Key Takeaways

US 6,534,070 covers a specific azelaic acid hydrogel formulation, not azelaic acid generally.
Claim 1 requires azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, lecithin, water, salts, and a hydrogel.
Claims 5 and 6 target concentration ranges that closely correspond to a Finacea-type formulation.
Claims 8 and 9 cover treatment of rosacea and other skin conditions using the claimed composition.
Claim 12 specifically covers benzoic acid-containing formulations.
The patent issued March 18, 2003, and its reported US expiration date was June 22, 2020.
The patent is expired and no longer blocks generic azelaic acid gel entry.
Finacea is a small-molecule drug, so biosimilar law does not apply.
Historical design-around options included omitting lecithin, replacing the polyacrylic acid or polysorbate, and using a non-hydrogel vehicle.
Current commercial risk arises from generic competition, FDA approval, manufacturing, and later patent families rather than from US 6,534,070.

FAQs About US Patent 6,534,070

Does US 6,534,070 cover all 15% azelaic acid gels?

No. The product must also satisfy the required excipient and dosage-form limitations, including lecithin, a triacylglyceride, propylene glycol, a polysorbate, an aqueous phase, and a hydrogel.

Is a 20% azelaic acid cream covered by the patent?

Not automatically. The 20% concentration is within claim 1, but a cream would need to satisfy the other limitations. A formulation without lecithin or without the claimed hydrogel structure would not literally meet claim 1.

Can a generic manufacturer launch a 15% azelaic acid gel after 2020?

The expired patent does not prevent launch. The manufacturer must still obtain FDA approval and satisfy applicable ANDA, quality, bioequivalence, labeling, and manufacturing requirements.

Does claim 8 cover treatment of acne with any azelaic acid product?

No. Claim 8 is dependent on claim 1. It requires use of the specific claimed composition, not merely any azelaic acid product.

Are foreign patents corresponding to US 6,534,070 also expired?

Not necessarily. Foreign family members have independent terms, prosecution histories, and regulatory extensions. US expiration does not determine the status of corresponding foreign rights.

References

U.S. Food and Drug Administration. (n.d.). Finacea (azelaic acid) gel, 15% prescribing information. Drugs@FDA.
United States Patent and Trademark Office. (2003). U.S. Patent No. 6,534,070, pharmaceutical composition containing azelaic acid. Washington, DC: U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	197 53 044	Nov 19, 1997
Germany	198 08 086	Feb 20, 1998

PCT Information
PCT Filed	November 18, 1998	PCT Application Number:	PCT/EP98/07370
PCT Publication Date:	May 27, 1999	PCT Publication Number:	WO99/25332

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	013769	⤷ Start Trial
Austria	210438	⤷ Start Trial
Australia	1755199	⤷ Start Trial
Australia	743437	⤷ Start Trial
Brazil	9814214	⤷ Start Trial
Canada	2311128	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,534,070

Summary for Patent: 6,534,070